Objective: The purpose of this study was to design and optimize a novel drug nanoparticles-loaded oral fast dissolving film (NP-OFDF) using Box-Behnken design-response surface methodology.
Methods: Drug nanosuspensions produced from high pressure homogenization were transformed into oral fast dissolving film containing drug nanoparticles by casting methods. Herpetrione (HPE), a novel and potent antiviral agent with poor water solubility that was extracted from Herpetospermum caudigerum, was studied as the model drug. The formulations of oral fast dissolving film containing HPE nanoparticles (HPE-NP-OFDF) were optimized by employing Box-Behnken design-response surface methodology and then systematically characterized.
Results: The optimized HPE-NP-OFDF was disintegrated in water within 20 s with reconstituted nanosuspensions particle size of 299.31 nm. Scanning electron microscopy (SEM) images showed that well-dispersed HPE nanoparticles with slight adhesion to each other were exposed on the surface of film or embedded in film. The X-ray diffractogram (XRD) analysis suggested that HPE in the HPE-NP-OFDF was in the amorphous state. In-vitro release study, approximate 77.23% of HPE was released from the HPE-NP-OFDF within 5 min, which was more than eight times compared with that of HPE raw materials (9.57%).
Conclusion: The optimized HPE-NP-OFDF exhibits much faster drug release rates compared to HPE raw material, which indicated that this novel NP-OFDF may provide a potential opportunity for oral delivery of drugs with poor water solubility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/03639045.2014.884116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
JAMA
January 2025
Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Importance: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. Whether a sequential strategy of these oral agents results in noninferior perinatal outcomes compared with insulin alone is unknown.
Objective: To test whether a treatment strategy of oral glucose-lowering agents is noninferior to insulin for prevention of large-for-gestational-age infants.
Differential Association of Salivary Proinflammatory Mediators with Type 2 Diabetes: A Network Meta-Analysis.
Iran J Public Health
December 2024
Medical Department, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.
Background: Salivary compounds can be used as diagnostic markers for changes in the oral cavity that cause oral problems in type 2 diabetes mellitus (T2DM).
Methods: This meta-analysis searched PubMed/Medline, EMBASE, Scopus and Cochrane Library, and the Web of Science until Nov 2023. The observational studies included patients with T2DM and healthy controls aged > 18 yr with no oral health problems or systematic or periodontal diseases.
Chelidonic acid abrogates oxidative stress and memory dysfunction in experimental aging rats.
Turk J Biol
October 2024
Neuropyschopharmacology Application and Research Center, Üsküdar University, İstanbul, Turkiye.
Background/aim: In an aging model established using male Wistar albino rats via the administration of D-galactose (D-gal), the aim of this study was to examine the effects of chelidonic acid (CA) on cognitive function and the levels of glutathione (GSH), malondialdehyde (MDA), total antioxidant status (TAS), and brain-derived neurotrophic factor (BDNF).
Materials And Methods: Thirty-two, three-month-old Wistar albino male rats (n = 8) were divided into four groups, as the control (C) group, CA group (2 mg/kg of CA via oral gavage), D-gal group (150 mg/kg of D-gal, subcutaneously), and D-gal + CA group (150 mg/kg of D-gal and 2 mg/kg of CA). Following overnight fasting, the 10-week trial was concluded with intramuscular injections of anesthetic drugs xylazine (8-10 mg/kg) and ketamine (80-100 mg/kg), and subsequently, the collection of cardiac blood.
Association between decreased occlusal support and diabetes mellitus diagnosed by the oral glucose tolerance test with and without periodontal disease: The Suita Study.
J Prosthodont Res
January 2025
Department of Geriatric Dentistry, Osaka Dental University, Osaka, Japan.
Purpose: Several studies have reported a close association between periodontal disease (PD) and diabetes mellitus (DM). In addition, the decline in masticatory function due to decreased occlusal support may worsen DM due to poor nutritional intake. We aimed to elucidate the relationship between PD, decreased occlusal support, and DM.
View Article and Find Full Text PDFPharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS.
Front Pharmacol
December 2024
Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Introduction: MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.
Methods: A fast ultra-high performance liquid chromatography-tandem quadrupole mass spectrometry method was developed for the determination of MRTX1133 in rat plasma, tissue homogenate, and urine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!